Cristina Fillat

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2778443/publications.pdf

Version: 2024-02-01

89 papers	2,630 citations	201674 27 h-index	214800 47 g-index
90 all docs	90 docs citations	90 times ranked	4173 citing authors

#	Article	IF	Citations
1	Aberrant TIMP-1 overexpression in tumor-associated fibroblasts drives tumor progression through CD63 in lung adenocarcinoma. Matrix Biology, 2022, 111, 207-225.	3.6	9
2	Codon Usage and Adenovirus Fitness: Implications for Vaccine Development. Frontiers in Microbiology, 2021, 12, 633946.	3.5	10
3	Transgene codon usage drives viral fitness and therapeutic efficacy in oncolytic adenoviruses. NAR Cancer, 2021, 3, zcab015.	3.1	1
4	Inhibition of miR-222 by Oncolytic Adenovirus-Encoded miRNA Sponges Promotes Viral Oncolysis and Elicits Antitumor Effects in Pancreatic Cancer Models. Cancers, 2021, 13, 3233.	3.7	7
5	Preclinical testing of oncolytic adenovirus sensitivity in patient-derived tumor organoids. STAR Protocols, 2021, 2, 101017.	1.2	6
6	Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma. Cancer Research, 2020, 80, 276-290.	0.9	25
7	The Value of Mouse Models of Rare Diseases: A Spanish Experience. Frontiers in Genetics, 2020, 11, 583932.	2.3	12
8	Arming Oncolytic Adenoviruses: Effect of Insertion Site and Splice Acceptor on Transgene Expression and Viral Fitness. International Journal of Molecular Sciences, 2020, 21, 5158.	4.1	5
9	The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities. Cancers, 2020, 12, 2106.	3.7	55
10	MiR-93 is related to poor prognosis in pancreatic cancer and promotes tumor progression by targeting microtubule dynamics. Oncogenesis, 2020, 9, 43.	4.9	15
11	Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses. EBioMedicine, 2020, 56, 102786.	6.1	35
12	Germline Mutations in FAF1 Are Associated With Hereditary Colorectal Cancer. Gastroenterology, 2020, 159, 227-240.e7.	1.3	18
13	Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses. Theranostics, 2020, 10, 2744-2758.	10.0	17
14	Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses. Cancers, 2020, 12, 1034.	3.7	15
15	Mutations in TIMM50 cause severe mitochondrial dysfunction by targeting key aspects of mitochondrial physiology. Human Mutation, 2019, 40, 1700-1712.	2.5	16
16	Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer. Molecular Therapy, 2019, 27, 230-243.	8.2	24
17	DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth. Gut, 2019, 68, 1465-1476.	12.1	52
18	Zeb1 in Stromal Myofibroblasts Promotes Kras-Driven Development of Pancreatic Cancer. Cancer Research, 2018, 78, 2624-2637.	0.9	15

#	Article	IF	Citations
19	Terapias avanzadas en enfermedades raras. Arbor, 2018, 194, 467.	0.3	1
20	DYRK1A Kinase Positively Regulates Angiogenic Responses in Endothelial Cells. Cell Reports, 2018, 23, 1867-1878.	6.4	34
21	Deciphering microRNA targets in pancreatic cancer using miRComb R package. Oncotarget, 2018, 9, 6499-6517.	1.8	8
22	Translational reprogramming in tumour cells can generate oncoselectivity in viral therapies. Nature Communications, 2017, 8, 14833.	12.8	18
23	Stress-Induced MicroRNA-708 Impairs Î²-Cell Function and Growth. Diabetes, 2017, 66, 3029-3040.	0.6	39
24	Implications of MicroRNAs in Oncolytic Virotherapy. Frontiers in Oncology, 2017, 7, 142.	2.8	21
25	A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel. Oncotarget, 2017, 8, 22700-22715.	1.8	15
26	The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer. Oncotarget, 2016, 7, 48265-48279.	1.8	10
27	Codon optimization of the adenoviral fiber negatively impacts structural protein expression and viral fitness. Scientific Reports, 2016, 6, 27546.	3.3	19
28	Genome-wide miR-155 and miR-802 target gene identification in the hippocampus of Ts65Dn Down syndrome mouse model by miRNA sponges. BMC Genomics, 2015, 16, 907.	2.8	30
29	AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-ÎºB mediated uPAR activation. Molecular Cancer, 2015, 14, 146.	19.2	6
30	Late-phase miRNA-controlled oncolytic adenovirus for selective killing of cancer cells. Oncotarget, 2015, 6, 6179-6190.	1.8	16
31	DYRK1A-mediated phosphorylation of GluN2A at Ser1048 regulates the surface expression and channel activity of GluN1/GluN2A receptors. Frontiers in Cellular Neuroscience, 2014, 8, 331.	3.7	39
32	A genetic fiber modification to achieve matrix-metalloprotease-activated infectivity of oncolytic adenovirus. Journal of Controlled Release, 2014, 192, 148-156.	9.9	9
33	uPAR-controlled oncolytic adenoviruses eliminate cancer stem cells in human pancreatic tumors. Stem Cell Research, 2014, 12, 1-10.	0.7	11
34	MiR-148a- and miR-216a-regulated Oncolytic Adenoviruses Targeting Pancreatic Tumors Attenuate Tissue Damage Without Perturbation of miRNA Activity. Molecular Therapy, 2014, 22, 1665-1677.	8.2	33
35	Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer. Current Pharmaceutical Design, 2014, 20, 6513-6521.	1.9	9
36	Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome. Experimental Neurology, 2013, 239, 229-234.	4.1	9

#	Article	IF	Citations
37	Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome. Neurobiology of Disease, 2013, 52, 117-127.	4.4	67
38	Intraductal Delivery of Adenoviruses Targets Pancreatic Tumors in Transgenic Ela-myc Mice and Orthotopic Xenografts. Oncotarget, 2013, 4, 94-105.	1.8	20
39	Editorial - Advances in Oncolytic Antitumour Adenoviral Therapies: Three Key Aspects. The Open Gene Therapy Journal, 2013, 3, 8-8.	1.2	0
40	Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3136-45.	7.1	155
41	Gene therapy for Down syndrome. Progress in Brain Research, 2012, 197, 237-247.	1.4	6
42	Other Well-Defined Immunodeficiency Syndromes. , 2012, , 343-368.		0
43	Diabetes Risk Gene and Wnt Effector Tcf7l2/TCF4 Controls Hepatic Response to Perinatal and Adult Metabolic Demand. Cell, 2012, 151, 1595-1607.	28.9	202
44	Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models. Cancer Letters, 2012, 317, 16-23.	7.2	66
45	Connexin-26 Is a Key Factor Mediating Gemcitabine Bystander Effect. Molecular Cancer Therapeutics, 2011, 10, 505-517.	4.1	33
46	Behavioral Characterization of a Mouse Model Overexpressing DSCR1/ RCAN1. PLoS ONE, 2011, 6, e17010.	2.5	42
47	Oncolytic Adenoviruses Armed with Thymidine Kinase Can Be Traced by PET Imaging and Show Potent Antitumoural Effects by Ganciclovir Dosing. PLoS ONE, 2011, 6, e26142.	2.5	27
48	Pancreatic Cancer Gene Therapy: From Molecular Targets to Delivery Systems. Cancers, 2011, 3, 368-395.	3.7	8
49	X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood, 2010, 115, 3231-3238.	1.4	178
50	Cell cycle control pathways act as conditioning factors for TK/GCV sensitivity in pancreatic cancer cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2010, 1803, 1175-1185.	4.1	18
51	Regulated Segregation of Kinase Dyrk1A during Asymmetric Neural Stem Cell Division Is Critical for EGFR-Mediated Biased Signaling. Cell Stem Cell, 2010, 7, 367-379.	11.1	71
52	Insights from Mouse Models to Understand Neurodegeneration in Down Syndrome. CNS and Neurological Disorders - Drug Targets, 2010, 9, 429-438.	1.4	8
53	Controlling Adenoviral Replication to Induce Oncolytic Efficacy~!2009-11-11~!2010-01-02~!2010-05-26~!. The Open Gene Therapy Journal, 2010, 3, 15-23.	1.2	4
54	Keratin 7 promoter selectively targets transgene expression to normal and neoplastic pancreatic ductal cellsin vitroandin vivo. FASEB Journal, 2009, 23, 1366-1375.	0.5	17

#	Article	IF	Citations
55	Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy. Molecular Cancer Therapeutics, 2009, 8, 3098-3107.	4.1	9
56	Antitumor Therapy Based on Cellular Competition. Human Gene Therapy, 2009, 20, 728-738.	2.7	6
57	Urokinase-Type Plasminogen Activator Receptor Transcriptionally Controlled Adenoviruses Eradicate Pancreatic Tumors and Liver Metastasis in Mouse Models. Neoplasia, 2009, 11, 518-IN6.	5.3	31
58	DYRK1A-Dosage Imbalance Perturbs NRSF/REST Levels, Deregulating Pluripotency and Embryonic Stem Cell Fate in Down Syndrome. American Journal of Human Genetics, 2008, 83, 388-400.	6.2	139
59	Targeting Dyrk1A with AAVshRNA Attenuates Motor Alterations in TgDyrk1A, a Mouse Model of Down Syndrome. American Journal of Human Genetics, 2008, 83, 479-488.	6.2	60
60	Two novel mutations identified in the Wiskott-Aldrich syndrome protein gene cause Wiskott-Aldrich syndrome and thrombocytopenia. International Journal of Molecular Medicine, 2007, 19, 777.	4.0	1
61	Two novel mutations identified in the Wiskott-Aldrich syndrome protein gene cause Wiskott-Aldrich syndrome and thrombocytopenia. International Journal of Molecular Medicine, 2007, 19, 777-82.	4.0	2
62	Non-invasive bioluminescence imaging for monitoring herpes simplex virus type 1 hematogenous infection. Microbes and Infection, 2006, 8, 1330-1338.	1.9	26
63	Pitfalls And Hopes in Down Syndrome Therapeutic Approaches: In the Search for Evidence-Based Treatments. Behavior Genetics, 2006, 36, 454-468.	2.1	17
64	A novel Wiskott-Aldrich syndrome protein (WASP) complex mutation identified in a WAS patient results in an aberrant product at the C-terminus from two transcripts with unusual polyA signals. Journal of Human Genetics, 2006, 51, 92-97.	2.3	12
65	Transgenic mice overexpressing the full-length neurotrophin receptor TrkC exhibit increased catecholaminergic neuron density in specific brain areas and increased anxiety-like behavior and panic reaction. Neurobiology of Disease, 2006, 24, 403-418.	4.4	50
66	Targeting the CYP2B1/Cyclophosphamide Suicide System to Fibroblast Growth Factor Receptors Results in a Potent Antitumoral Response in Pancreatic Cancer Models. Human Gene Therapy, 2006, 17, 1187-1200.	2.7	14
67	Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. Journal of General Virology, 2006, 87, 2487-2495.	2.9	69
68	Targeting the CYP2B1/Cyclophosphamide Suicide System to Fibroblast Growth Factor Receptors Results in a Potent Antitumoral Response in Pancreatic Cancer Models. Human Gene Therapy, 2006, .	2.7	0
69	Tat8â€“TK/GCV Suicide Gene Therapy Induces Pancreatic Tumor Regression In Vivo. Human Gene Therapy, 2005, 16, 1377-1388.	2.7	17
70	Enhancement of Gemcitabine-Induced Apoptosis by Restoration of p53 Function in Human Pancreatic Tumors. Oncology, 2005, 68, 179-189.	1.9	18
71	Tat8-TK/GCV Suicide Gene Therapy Induces Pancreatic Tumor Regression In Vivo. Human Gene Therapy, 2005, .	2.7	0
72	Regression of Advanced Diabetic Nephropathy by Hepatocyte Growth Factor Gene Therapy in Rats. Diabetes, 2004, 53, 1119-1127.	0.6	79

#	Article	IF	Citations
73	Adenovirus-Mediated Retinoblastoma 94 Gene Transfer Induces Human Pancreatic Tumor Regression in a Mouse Xenograft Model. Clinical Cancer Research, 2004, 10, 1454-1462.	7.0	11
74	Intramuscular SP1017-formulated DNA electrotransfer enhances transgene expression and distributes hHGF to different rat tissues. Journal of Gene Medicine, 2004, 6, 111-118.	2.8	36
75	Identification and characterization of a novel splice-site mutation in a patient with Wiskott-Aldrich syndrome. Journal of Human Genetics, 2003, 48, 590-593.	2.3	4
76	Wiskottâ€“Aldrich syndrome in a female with skewed X-chromosome inactivation. Blood Cells, Molecules, and Diseases, 2003, 31, 332-337.	1.4	30
77	Autoimmune Thyroiditis After Bone Marrow Transplantation in a Boy With Wiskott-Aldrich Syndrome. Journal of Pediatric Hematology/Oncology, 2002, 24, 772-776.	0.6	10
78	Intratumoral activation of cyclophosphamide by retroviral transfer of the cytochrome P450 2B1 in a pancreatic tumor model. Combination with the HSVtk/GCV system. Journal of Gene Medicine, 2002, 4, 141-149.	2.8	19
79	Murine models for Down syndrome. Physiology and Behavior, 2001, 73, 859-871.	2.1	62
80	Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and connexin26 genes in pancreatic cells results in variable efficiency on the bystander killing: Implications for gene therapy. International Journal of Cancer, 2001, 94, 81-88.	5.1	32
81	Identification of WASP mutations in 14 Spanish families with Wiskott-Aldrich syndrome. American Journal of Medical Genetics Part A, 2001, 100, 116-121.	2.4	22
82	Two novel mutations in the WASP gene in Wiskott-Aldrich patients of Chile origin: W64R and A124E. Human Mutation, 2000, 15, 487-487.	2.5	1
83	Chapter 5.9 Modelling Down syndrome in mice. Handbook of Behavioral Neuroscience, 1999, 13, 895-913.	0.0	1
84	Tissue-specific Expression and Dietary Regulation of Chimeric Mitochondrial 3-Hydroxy-3-methylglutaryl Coenzyme A Synthase/Human Growth Hormone Gene in Transgenic Mice. Journal of Biological Chemistry, 1996, 271, 7529-7534.	3.4	9
85	Fluorescence-Based Selection of Retrovirally Transduced Cells in the Absence of a Marker Gene: Direct Selection of Transduced Type B Niemann-Pick Disease Cells and Evidence for Bystander Correction. Human Gene Therapy, 1995, 6, 975-983.	2.7	24
86	Regulated expression of human insulin in the liver of transgenic mice corrects diabetic alterations. FASEB Journal, 1994, 8, 440-447.	0.5	75
87	Epidermal growth factor inhibits phosphoenolpyruvate carboxykinase gene expression in rat hepatocytes in primary culture. FEBS Letters, 1993, 318, 287-291.	2.8	14
88	Determination of glucose-6-phosphatase activity using the glucose dehydrogenase-coupled reaction. Analytical Biochemistry, 1988, 173, 185-189.	2.4	141
89	Novel membrane cell projection defects in Wiskott-Aldrich syndrome B cells. International Journal of Molecular Medicine, 0, , .	4.0	1